The EPOCH Study (Eplerenone on Top of ACE Inhibition in Chronic Kidney Disease Patients With Hypertension)
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
In a prospective single centre placebo-controlled trial over ten weeks, 24 CKD II-III
patients (eGFR 30-89 ml/min per 1.73 m2) with DM II will be randomized to enalapril 20mg per
day after a two week run-in phase. Thereafter, patients will either receive eplerenone 25mg
(n=12) or a placebo (n=12) for eight weeks. Eplerenone will be increased to 50mg under close
monitoring of serum potassium levels. Employing a novel mass-spectrometry ( MS)-based method,
quantification of up to 10 different Ang metabolites (Ang I, Ang II, Ang 1-7, Ang 1-9, Ang
2-10, Ang 1-5, Ang 2-7, Ang 3-7, Ang 3-8 and Ang 2-8) will be performed simultaneously out of
blood sera (after run-in phase and after 10 weeks).